title: Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
abstract: An inactivated, alum-adjuvanted, whole-virion H5N1 vaccine had been evaluated previously. Hemagglutination inhibition (HI) assays showed that the antibody levels declined significantly, with 4.8%-20.8% and 0%-18.8% of participants retaining seroprotection (HI titer >or=1:40) 6 and 12 months after the second dose, respectively. A third dose of the same vaccine given 12 months after the second dose significantly boosted immune responses. Thirty days after the third dose in the 1.25-, 2.5-, 5-, and 10-microg dose groups, 29.4%, 31.3%, 78.6%, and 90.0% of participants had HI titers >or=1:40, and 52.9%, 81.2%, 92.9%, and 100% of participants had microneutralization titers >or=1:40, respectively. Both the 5-microg and 10-microg doses met European Union criteria.
authors.affiliation: China-Japan Friendship Hospital, Beijing, China.
authors.forename: Jiang-Tao
authors.initials: JT
authors.lastname: Lin
authors.forename: Chang-Gui
authors.initials: CG
authors.lastname: Li
authors.forename: Xu
authors.initials: X
authors.lastname: Wang
authors.forename: Nan
authors.initials: N
authors.lastname: Su
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Yuan-Zheng
authors.initials: YZ
authors.lastname: Qiu
authors.forename: Meng
authors.initials: M
authors.lastname: Yang
authors.forename: Jiang-Ting
authors.initials: JT
authors.lastname: Chen
authors.forename: Han-Hua
authors.initials: HH
authors.lastname: Fang
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Dong
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Yin
authors.forename: Zi-Jian
authors.initials: ZJ
authors.lastname: Feng
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000276:immunology; D014771:Virion / Q000276:immunology; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated